Strategies to Increase the Value of Drug Therapy

 Strategies to Increase the Value of Drug Therapy Edit
Strategies to Increase the Value of Drug Therapy Edit
Click here to register

Date: Tuesday, May 12
Time: 1:00 PM EST / 10:00 AM PST


Value is a concept that concerns all healthcare stakeholders.

Five Key Questions:
1. Do expensive drugs work good enough to support their price and deliver true value?
        2. How can pharmaceutical value be integrated into therapeutic decisions
        3. Can a single pharmaceutical value proposition be used for all stakeholders?
        4. How can you balance the benefits obtained from a drug therapy with the costs to obtain them?
        5. What decision-support tools can be used to promote high-value cancer drug therapy?

Objectives:

  • Define value-based pharmaceutical care
  • Gain an appreciation for different perceptions of value by key stakeholders in health care (providers, payers, patients, manufacturers)
  • Increase awareness of strategies and decision-support tools to increase the value of cancer drug therapy (guidelines, pathways, drug class innovator reference, scorecards, etc)

Speaker:

Jim M. Koeller, MS, Professor, The University of Texas at Austin, Center for Pharmacoeconomic Studies, and the UT Health

Jim Koeller is Professor at the Center for Pharmacoeconomic Studies and holds the Eli Lilly/CR Sublett Endowed Fellowship in Pharmacy at the University of Texas at Austin College of Pharmacy. He is Adjoint Professor of Medicine and Oncology at the University of Texas Health Science Center at San Antonio. He previously worked in the Department of Human Oncology at Wisconsin Comprehensive Cancer Center, Madison, where he coordinated the Phase I Drug Development Program. Jim has published more than 250 articles, abstracts, and book chapters in the areas of oncology practice, pharmacoeconomics, new drug development, and supportive care for the cancer patient. In addition, he has made more than 500 presentations related to oncology, supportive care, pharmacoeconomics, cancer disease management, pathway development and management, and healthcare economics.


Sponsored by:




Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.